China is Betting on Brain Wearables, the US on Implants. Who Wins?

While American brain-computer interface companies such as Neuralink are betting that the future lies beneath the skull, China is pursuing the opposite strategy: make neurotechnology wearable, affordable and ubiquitous. Rather than waiting for surgical breakthroughs, Beijing has mobilized ministries, hospitals, insurers and private capital behind non-invasive devices that can reach millions of users without an operating room, turning brain-computer interfaces from a moonshot into an industrial policy.

The most consequential divide in brain-computer interface technology may not be a scientific one. It may be geopolitical. In the United States, the field is defined by the ambitions of a small number of billionaire-funded companies willing to place a decades-long, high-risk wager on surgical implants.

In China, the same technology is being built as a matter of industrial policy, with state ministries, hospital systems and insurance regulators moving in coordinated lockstep toward a very different endpoint: a wearable device cheap and safe enough for a mass consumer market.

The scale of that state coordination is difficult to overstate. This year’s national government work report, which set policy priorities for the 15th Five-Year Plan covering 2026 to 2030, named brain-computer interfaces, or B.C.I., a key future industry for the first time, placing the technology alongside quantum computing and next-generation semiconductors as a pillar of what officials call new quality productive forces.

Only a handful of frontier technologies made that list, according to an analysis published by China policy analyst Dirk van der Kley, underscoring how much institutional weight Beijing is prepared to put behind the sector.

Beijing thinks in terms of not just one breakthrough technology, but the whole supply chain.
  — Paul Triolo, partner, Albright Stonebridge Group / DGA Group

That whole-supply-chain approach is already visible on the ground. Seven ministries, including the Ministry of Industry and Information Technology and the National Medical Products Administration, jointly issued an implementation plan for the B.C.I. industry, and provincial governments have since layered on their own targets.

One regional plan reviewed by China Briefing calls for the completion of medical registration for three invasive and five non-invasive B.C.I. products by 2027, alongside the province’s first invasive implant surgery and treatment of more than 50,000 patients annually. By 2030, the same roadmap envisions 3,000 invasive procedures a year nationally and applications reaching into manufacturing and eldercare, not just medicine.

China has also begun folding the technology into its national medical insurance architecture, a step with outsized commercial consequence. Regional authorities are exploring pricing frameworks for B.C.I.-related services under basic medical insurance, according to a Beijing Review report, a signal that the government now treats implantable and wearable neurotechnology as a legitimate, reimbursable medical category rather than an experimental fringe procedure. That distinction matters because insurance coding, more than any single scientific breakthrough, is often what determines whether a therapy reaches a mass patient population.

The Money Behind the Divide
Global BCI market, 2026 (narrow definition, ex. cochlear/DBS)	$3.3B–$3.8B
Projected market size by 2035	$13B–$15B
Compound annual growth rate, 2026–2035	16–17%
Global BCI venture funding, 2024	$2.3B
China BCI financing deals, Q1 2026 (17 deals)	$551M
China BCI financing, full-year 2025	$212M
Non-invasive share of China’s BCI market, 2024	~82%
Neuralink cumulative primary funding, mid-2026	~$1.85B

Sources: Neuroba market analysis; China.org.cn, citing IT Juzi data; China Briefing, citing CCID Consulting.

The China figure is especially telling. Financing for domestic B.C.I. companies more than tripled year over year in the first quarter of 2026 alone, according to the venture data platform IT Juzi, cited by China.org.cn, already surpassing the full-year total recorded in 2025. Much of that capital is flowing not from specialist deep-tech funds but from major Chinese internet companies, a pattern that mirrors how domestic capital chased electric vehicles and solar manufacturing a decade earlier once Beijing designated them strategic.

Why Non-Invasive Is Winning the Argument, for Now

Globally, non-invasive systems, primarily electroencephalography, or EEG, headsets and dry-electrode wearables, still account for the majority of installed B.C.I. revenue. Analysts at Coherent Market Insights put the non-invasive share at roughly 62 percent of the market in 2026, a dominance they attribute to lower cost, faster regulatory clearance and greater comfort for both patients and, eventually, consumers. That calculus is central to the strategy pursued by BrainCo, the Hangzhou startup at the center of China’s wearable push, which has raised roughly $280 million in a round led by IDG Capital and Walden International.

Yet the technical case for going non-invasive is contested even among specialists who otherwise agree the field is entering a commercial phase. Skull-penetrating signal acquisition remains, in the view of implant proponents, the only realistic path to the fidelity required for complex motor control or high-bandwidth communication. Ultrasound-based approaches, which sit between the two camps by avoiding surgery while still probing deeper brain structures, are drawing serious venture interest, including from Sam Altman-backed Merge Labs in the United States and China’s Gestala.

Non-invasive is like trying to capture light in distant galaxies.
  — Alex Zhavoronkov, chief executive, Insilico Medicine

Market researchers at Mordor Intelligence, in a separate assessment of the narrower neurotechnology B.C.I. segment, estimate the category at $1.33 billion in 2026, expanding at roughly 15 percent annually through 2031. Within that data set, electroencephalography still captures the majority of technology revenue, but real-time functional M.R.I. approaches and partially invasive systems, which balance surgical risk against signal quality, are growing fastest, at close to 16 percent a year, according to Mordor Intelligence. The firm also notes that Chinese researchers at NeuroXess have demonstrated roughly 71 percent decoding accuracy for Mandarin syllables in early trials, a benchmark that narrows, though does not close, the performance gap with implant-based speech systems developed in the United States.

The Disease Burden Driving Both Bets

Underlying both national strategies is a demographic reality neither government can engineer away. Neurological disorders now affect more than 3.4 billion people worldwide, according to global disease burden estimates cited by Mordor Intelligence’s market analysis, making them collectively the leading cause of illness and disability on the planet. Parkinson’s disease alone affected an estimated 11.77 million people globally as of 2021, a figure that continues to climb as populations in China, Japan and the West age. That burden, rather than any single scientific milestone, is what forecasters describe as the primary demand driver for therapeutic B.C.I. devices over the next decade.

Regulatory momentum has followed the epidemiology. In the United States, the F.D.A.’s Breakthrough Device pathway has cleared a string of implant and closed-loop systems for clinical study, including CorTec’s cortical stimulation platform for stroke rehabilitation. China’s own regulator, the National Medical Products Administration, approved what officials describe as the country’s first minimally invasive B.C.I. device for commercial use in 2026, developed by Neuracle Medical Technology to help restore hand function after spinal cord injury, according to reporting reviewed alongside China Briefing’s regulatory tracking. Clinical validation, once the province of a handful of American university hospitals, is now happening on both sides of the Pacific simultaneously.

The Unresolved Question: Who Actually Buys This?

For all the policy architecture and capital formation, the industry’s own analysts concede that the addressable market beyond therapeutic use, the much-discussed prospect of augmenting healthy human cognition, remains almost entirely theoretical. Rui Ma, founder of the Tech Buzz China research platform, has argued that while today’s clinical applications can meaningfully change the lives of severely impaired patients, the larger commercial opportunity in augmentation is not close to being realized, calling that vision closer to science fiction than product roadmap.

That gap between policy ambition and consumer reality is precisely where the American and Chinese models are likely to diverge in outcome, even as they converge in urgency. Washington’s approach remains dependent on the risk tolerance of a small number of billionaire financiers willing to fund a technology whose payoff may be a decade or more away. Beijing, by contrast, is attempting to manufacture demand through insurance policy, hospital partnerships and provincial industrial targets, a strategy that has worked before, in solar panels and electric vehicles, but has never been tested on a technology that requires convincing consumers to put a device, however non-invasive, directly against or inside their skulls.

Investment bank Jefferies, in a research note reviewing the sector, concluded that invasive implants and ultrasound-based methods represent the most technically promising frontiers, while cautioning that conventional non-invasive systems remain limited by how precisely they can capture and interpret brain signals. Whether that technical caveat matters to a market being built as much by government mandate as by consumer demand is the question that will determine which country’s bet on the brain pays.

Stay ahead of the stories shaping our world. Subscribe to Impact Newswire for timely, curated insights on global tech, business, and innovation all in one place.

Dive deeper into the future with the Cause Effect 4.0 Podcast, where we explore the ideas, trends, and technologies driving the global AI conversation.

Got a story to share? Pitch it to us at info@impactnews-wire.com and reach the right audience worldwide